Search

Your search keyword '"Finegold SM"' showing total 481 results

Search Constraints

Start Over You searched for: Author "Finegold SM" Remove constraint Author: "Finegold SM"
481 results on '"Finegold SM"'

Search Results

51. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

52. Determination of bft gene subtypes in Bacteroides fragilis clinical isolates.

53. Development of a flow chart for identification of gram-positive anaerobic cocci in the clinical laboratory.

54. Alistipes onderdonkii sp. nov. and Alistipes shahii sp. nov., of human origin.

55. Bacteraemia caused by Anaerotruncus colihominis and emended description of the species.

56. In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.

57. Isolation of a strictly anaerobic strain of Staphylococcus epidermidis.

58. Porphyromonas somerae sp. nov., a pathogen isolated from humans and distinct from porphyromonas levii.

59. "Bacteroides goldsteinii sp. nov." isolated from clinical specimens of human intestinal origin.

60. Clostridium clostridioforme: a mixture of three clinically important species.

61. Evaluation of 16S rRNA sequencing and reevaluation of a short biochemical scheme for identification of clinically significant Bacteroides species.

62. Fastidiosipila sanguinis gen. nov., sp. nov., a new Gram-positive, coccus-shaped organism from human blood.

63. Fatal septicemia due to Clostridium hathewayi and Campylobacter hominis.

64. "Bacteroides nordii" sp. nov. and "Bacteroides salyersae" sp. nov. isolated from clinical specimens of human intestinal origin.

65. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.

67. Porphyromonas uenonis sp. nov., a pathogen for humans distinct from P. asaccharolytica and P. endodontalis.

68. Real-time PCR quantitation of clostridia in feces of autistic children.

69. In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.

70. Clostridium bartlettii sp. nov., isolated from human faeces.

71. Anaerotruncus colihominis gen. nov., sp. nov., from human faeces.

72. Anaerofustis stercorihominis gen. nov., sp. nov., from human feces.

73. Rapid identification of Gram-positive anaerobic coccal species originally classified in the genus Peptostreptococcus by multiplex PCR assays using genus- and species-specific primers.

74. Cetobacterium somerae sp. nov. from human feces and emended description of the genus Cetobacterium.

75. Rapid identification of the species of the Bacteroides fragilis group by multiplex PCR assays using group- and species-specific primers.

76. 16S ribosomal DNA sequence-based analysis of clinically significant gram-positive anaerobic cocci.

77. Clostridium bolteae sp. nov., isolated from human sources.

78. Use of 16S-23S rRNA spacer-region (SR)-PCR for identification of intestinal clostridia.

79. In vitro activities of faropenem against 579 strains of anaerobic bacteria.

80. Taxonomy--General comments and update on taxonomy of Clostridia and Anaerobic cocci.

81. Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media.

82. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.

83. Multilaboratory comparison of growth characteristics for anaerobes, using 5 different agar media.

84. Gastrointestinal microflora studies in late-onset autism.

85. Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults.

86. Activities of ABT-773 against microaerophilic and fastidious organisms.

87. In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria.

88. In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria.

89. Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse.

90. Short-term benefit from oral vancomycin treatment of regressive-onset autism.

91. Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents.

92. In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections.

93. A primer on anaerobic bacteria and anaerobic infections for the uninitiated.

94. Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis.

95. Comparison of recovery of anaerobic bacteria using the Anoxomat, anaerobic chamber, and GasPak jar systems.

96. Current susceptibility patterns of anaerobic bacteria.

97. In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.

98. Cellular fatty acid composition, soluble-protein profile, and antimicrobial resistance pattern of Eubacterium lentum.

99. Adherence of Bilophila wadsworthia to cultured human embryonic intestinal cells.

100. Biochemical and genetic characterization of a Prevotella intermedia/nigrescens-like organism.

Catalog

Books, media, physical & digital resources